Welcome to our dedicated page for Penumbra news (Ticker: PEN), a resource for investors and traders seeking the latest updates and insights on Penumbra stock.
Penumbra, Inc. (NYSE: PEN) is described in its public communications as the world’s leading thrombectomy company, with a portfolio focused on computer assisted vacuum thrombectomy (CAVT™) and related devices for serious vascular and neurovascular conditions. The Penumbra news feed on this page aggregates company announcements, clinical trial updates and capital markets communications that shape how investors and clinicians follow the PEN stock story.
Recent news includes the announcement of a definitive Agreement and Plan of Merger with Boston Scientific Corporation, under which a Boston Scientific subsidiary will merge with and into Penumbra, leaving Penumbra as a wholly owned subsidiary if the transaction closes. The joint press release details the planned cash-and-stock consideration and notes that, upon completion, Penumbra’s securities are expected to be delisted from the New York Stock Exchange and deregistered under the Securities Exchange Act of 1934.
Beyond M&A developments, Penumbra’s news flow features earnings releases and preliminary financial updates furnished via Form 8-K, outlining revenue trends, margins and non-GAAP measures such as constant currency revenue and adjusted EBITDA. These items provide context on the company’s operating performance and financial outlook as it continues to develop and commercialize thrombectomy and embolization technologies.
Penumbra also issues news around clinical research milestones. Notable examples include results from the pivotal STORM-PE randomized controlled trial, which evaluated CAVT using Penumbra’s Lightning Flash™ plus anticoagulation versus anticoagulation alone in acute intermediate-high risk pulmonary embolism. Company press releases describe superior reductions in right heart strain, thrombus burden and improvements in functional outcomes for patients treated with CAVT plus anticoagulation, with comparable safety profiles between treatment arms.
Additional news items cover leadership changes and investor relations activities, such as the appointment of a new company president and scheduled presentations at healthcare and investor conferences, including the J.P. Morgan Healthcare Conference and other sector events. These updates highlight how Penumbra’s management communicates with the investment community and discusses its clinical and commercial strategy.
By following this PEN news page, readers can review a consolidated stream of Penumbra’s press releases, transaction announcements, clinical trial disclosures and financial updates, all of which are sourced from official company communications and SEC-related materials.
Penumbra, Inc. reported strong financial results for the first quarter of 2024, with revenue reaching $278.7 million, a 15.4% increase over the previous year. The company's U.S. thrombectomy revenue saw a significant growth of 35.2%. The non-GAAP income from operations was $19.3 million, and adjusted EBITDA was $37.6 million with a margin of 13.5%. Penumbra's total revenue growth and U.S. thrombectomy revenue guidance for the full year 2024 are 16-20% and 27-30%, respectively. The company expects continued growth in revenue and gross margin expansion for the year.
Penumbra, Inc. (NYSE: PEN) will be presenting at the RBC Capital Markets Global Healthcare Conference on May 15, 2024. The webcast of the presentation will be available on the company's website for two weeks after the event.
FAQ
What is the current stock price of Penumbra (PEN)?
What is the market cap of Penumbra (PEN)?
